Guardant Health is a biotechnology company that specializes in developing advanced genomic tests for cancer patients
The company focuses on providing innovative liquid biopsy solutions, which involve analyzing circulating tumor DNA from blood samples to help detect and monitor cancers more effectively. Their tests are designed to aid physicians in making informed treatment decisions, enabling personalized medicine approaches that can improve patient outcomes. Through their cutting-edge technology and extensive research, Guardant Health aims to transform cancer care by delivering actionable insights and facilitating early detection and ongoing management of the disease.
Diagnostics company Guardant Health (NASDAQGH) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 30.2% year on year to $201.8 million. Its GAAP loss of $0.90 per share was 12.4% below analysts’ consensus estimates.
Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials.
Top performers in last week's mid-cap stocks: Oklo Inc., Tempus AI, Himax Tech, Super Group, NuScale Power, WNS Holdings, Guardant Health, Rigetti Computing.
Guardant Reveal test receives expanded Medicare coverage for colorectal cancer recurrence monitoring, enhancing revenue potential and clinical adoption.
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
Exact Sciences' Cologuard Plus test, now FDA-approved, offers a non-invasive screening option for adults 45+ at average risk for colorectal cancer. The test outperformed fecal immunochemical tests in detecting CRC and precancerous lesions.
